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Chronic lymphocytic leukemia is the most prevalent type of leukemia in the West. It is
characterized by an extremely variable clinical course. The aim of the study was to
detect the most frequent chromosomal abnormalities in patients with CLL using FISH,
and assess them regarding age, gender, clinical stage and CD38 and ZAP-70
expressions. We found 51.7% of the patients with chromosome abnormalities. The
most frequent one was del 13q14 in 34.5% of cases. It was associated to other
alterations in 17.2%. 17p13 deletions were found in 17.2% and trisomy 12 in 13.8%
(in isolation in 6.9% and associated to del 13q14, in 6.9% of the cases). An 11q22
deletion was found in one case associated to a 13q14 deletion. To better evaluate the
relationship between chromosome aberrations and other prognostic factors in CLL,
two cytogenetics groups were considered: favorable (13q deletion in isolation and no
alteration) and unfavorable outcomes (trisomy 12, 17p13 deletion, 11q22 deletion
and two simultaneous alterations).The unfavorable alterations were more frequently
seen among young individuals (<60y). There were more females (70%) than males in
this group (p=0.04). In relation to the Binet's staging system, patients with unfavorable
cytogenetic alterations, tended to be B and C stages, while in the favorable group
prevailed patients in stage A. Additionally, patients with poor prognostic cytogenetics
tended to express CD38 and ZAP-70 proteins. Rev. bras. hematol. hemoter. 2006;
28(1):5-10.
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Introduction
Chronic lymphocytic leukemia is the most prevalent
type of leukemia in the West.1 Approximately 65% of the
cases are diagnosed  in an asymptomatic phase and around
70% to 80% of the patients present low tumor masses.2
The disease is characterized by an extremely variable
clinical course, while some patients have an indolent course
and never require treatment, others present a quickly
progressive evolution and prompt treatment is required.3,5
The classical staging systems of the disease, Rai6 and
Binet's,7 are based on clinical and hematological features.
However in CLL early stages, neither system accurately
distinguishes patients who may rapidly transform into
aggressive disease from those who will remain with indolent
disease. Since the introduction of staging systems, there has
been a continuous effort to identify new prognostic factors
for CLL. Recently, new markers of prognostic impact have
been investigated and associated to poor prognosis including
unmutated VH genes (immunoglobulin heavy-chain variable
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genes) status, high expression of CD38 on the surface of the
leukemic cells and high expression of the ZAP-70 gene.8-14
Cytogenetic alterations have also been related with
prognosis in CLL.4,5,15 In that sense, there is a great interest
in identifying chromosome alterations that can define
subgroups of patients with different prognosis.
The most important numerical and structural
abnormalities found in CLL include trisomy 12 and deletions
in several chromosome regions, such as 13q14, 11q, and
17p13, as well as other less frequently occurring aberrations.16
Trisomy 12 is identified as the most common numeric
chromosome abnormality, being frequently associated with
atypical lymphocyte morphology, advanced disease and an
aggressive clinical course.17,18
Structural abnormalities more frequently involve the
long arm of chromosome 13 with different breakpoints,
including deletions of 13q14. Deletions or translocations of
the 13q14 have been associated with typical morphology
CLL and do not carry an adverse prognostic significance.17,19
A 11q deletion has been associated with rapidly
progressive disease, extensive lymphadenopathy, advanced
stages, shorter treatment-free intervals and shorter survival
times.16 Allelic loss of chromosome 17p, the site of the p53
gene, is often associated with poor clinical outcome and
drug resistance.20,21
More than half of the abnormal karyotypes are
constituted by single abnormalities, whereas complex
karyotypes are found in 10% to 15% of all patients.15
Any clonal chromosomal abnormality indicates a
poorer prognosis compared to a normal karyotype. However,
the complexity of the karyotype is a significant parameter.
Single abnormalities indicate a longer survival than multiple
abnormalities.22
Objective
The aim of our investigation was to detect the most
frequent chromosome anomalies in a group of 29 patients
with CLL by fluorescence in situ hybridization (FISH), using
probes specific for the chromosome 12 centromere, 13q14.3
(D13S319), 17p13.1 (p53) and 11q22 (ATM), and to relate
the results to age, gender, clinical stage, CD38 and ZAP-70
expression.
Materials and Methods
Peripheral blood samples were collected from 29
patients with CLL from Universidade Federal de São Paulo
and Hospital Servidor Público Estadual between 2002 and
2004. The diagnosis was based on morphology and
immunophenotype. This study was approved by the local
Ethics Committee.
The expression of CD38 was studied on leukemic cells
using flow cytometer (FACS calibur, Becton Dickinson, San
Jose) and performed together with the diagnostic immuno-
phenotypic analysis. The CD38 monoclonal antibody
conjugated with phycoerythrin (PE, BD) was used. Positivity
was considered when 30% or more cells expressed the
antigen.8
The expression of the ZAP-70 protein was determined
in cryopreserved leukemic cells, using the anti-ZAP-70
(UPSTATE) monoclonal antibody and the anti mouse IgG
antibody conjugated with fluorescein isothiocyanate
(DAKO), as the second antibody. Acquisition and analysis
were done by flow cytometry (FACS calibur, BD) using the
software CellQuest (BD). Values above 20% were considered
positive.14
FISH was performed using probes specific for the
chromosome 12 centromere, 13q14.3 (D13S319), 17p13.1
(p53) and 11q22 (ATM) (Vysis). Slides were prepared from
material fixed in methanol-acetic acid.
All four probes were set up separately on different
slides for each patient. Hybridization and detection of
hybridization signals were performed according to the
manufacturer's protocols. At least two technologists scored
the same case. For each probe, at least 100 nuclei were
evaluated. Images of FISH were captured through the
program MacProbe 4.4 of PowerGene System (Applied
Imaging Corporation, USA).
Peripheral blood samples from healthy individuals
were used as a control. Means and standard deviations (SD)
of the percentage of nuclei with hybridization signals were
calculated. Results were considered abnormal if the percent
of nuclei with the abnormal hybridization signal was > 2
SD from the mean.
Fisher's exact test was used to test whether there was
significant relation between FISH characteristics and age,
gender, Binet stage, CD38 and ZAP-70 expression.
Statistical significance was accepted at 5% (α=0.05).
Results
Fifteen patients (51.7%) presented chromosomal
abnormalities: 10 (34.5%) with a single aberration and five
(17.2%) with two anomalies. The remaining 14 cases (48.3%),
had no cytogenetic abnormality identified (Table 1).
The most frequently observed aberration was 13q14
deletions observed in 10 patients (34.5% of the total of ca-
ses and 66.6% of the abnormalities), in isolation in five
cases (17.2%) and associated to other anomalies in the other
five (trisomy 12, del 11q22 and del 17p13). 17p13 deletions
were found in five patients (17.2%), in isolation in three
and associated to del 13q14 in two, as already mentioned.
Trisomy 12 was isolated in two patients (6.9%), and
associated to deletion 13q14, in two (13.8% of the total ca-
ses and 26.7% of the alterations).
A 11q22 deletion was found in one case associated to
a 13q14 deletion (6.7% of the abnormalities) (Table 1).
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Table 2 demonstrates the frequencies of the
cytogenetics alterations studied in relation to age, gender,
Binet stage, CD38 and ZAP-70 expressions.
To better study the relationship between chromosome
aberrations and other prognostic factors in CLL, we
separated the patients in two cytogenetic groups: favorable
(isolated 13q deletion and no alterations) and unfavorable
outcomes (trisomy 12, 17p13 deletion, 11q22 deletion and
two simultaneous alterations) (Table 3).
We found that in relation to patients' age, the
unfavorable alterations were more frequently observed
among young individuals (57% of the <60 years) while these
alterations were found in only 27.2% of elderly patients
(above 60 years). Favorable alterations were seen more
frequently among elderly patients. However, this
difference was not statistically significant.
In relation to gender, there was a prevalence
of females (70%) in the worse prognostic group
and prevalence of males in the group with a better
prognosis (73%) (p = 0.04).
In relation to the Binet's staging system, the
patients with cytogenetic alterations of worse
prognosis, tended to be B and C stages (6/10 -
60%), while in the favorable group stage A
patients prevailed (11/19 - 57.8%).
All patients were evaluated for CD38
expression, with 10 positive cases (≥ =30%) for
this antigen. Patients with poor prognostic
cytogenetics tended to present with positive CD38
expression in comparison to the others (p=0.051).
The ZAP-70 expression was investigated in
28 cases and found positive in 13 patients. In the
group of unfavorable cytogenetics, six patients
(60%) were positive for ZAP-70 while in the
favorable group, there was a prevalence (58%) of
ZAP-70 negative individuals.
Discussion
CLL is characterized by a highly variable
clinical course: while some patients present quick
progressive evolutions, others have an indolent
course with more than 30 years of survival.22
At the time of diagnosis, it is often difficult
to distinguish patients who are likely to remain
stable from those who will progress and require
treatment. Prognostic factors have traditionally
relied on disease stage, based primarily on tumor
bulk. A number of new prognostic factors have
recently been proposed to better identify patients
at increased risk. These new directions are based
on cytogenetic alterations, as well as molecular
and immunophenotypic studies.23
Published data reveal that chromosomal
alterations are detected in only 30 to 40% of the cases by
conventional cytogenetics, while these indexes reach up to
82% when molecular cytogenetics (FISH) is used.4 In this
study we found chromosome alterations in 52% of the
patients with the 4 probes used.
Trisomy 12 is found, varying from 11.5 to 37% in
published series.24,25 In this study 13.8% of the patients
had trisomy 12, half of which were associated to 13q14
deletion.
Hjalmar et al (2001)18 studying sequential FISH for
the chromosome 12, demonstrated that the percentage of
cells with trisomy 12 increased during the follow-up period
in patients with signs of progressive disease requiring
therapy. They also demonstrated that the relative size of the
Table 1
Frequency of cytogenetics abnormalities detected by FISH in 29 patients with CLL
Abnormality n % total %
of patients  of abnormalities*
Abnormality 15 52
No abnormality 14 48
Trisomy 12 2 6,9ψ 13,3
Deletion 11q22 0 0ψ 0
Deletion 17q13 3 10,3ψ 20
Deletion 13q14 5 17,2ψ 33,3
del 13q14 + trisomy 12 2 6,9* 13,3
del 13q14 + 11q22 1 3,5* 6,7
del 13q14+ 17q13 2 6,9* 13,3
total 29 100 100
Obs: ψ total = 34,4%; * total = 17,3%; n =15
Table 2
Frequency of cytogenetics abnormality detected by FISH in 29 patients with CLL in relation with
 age, gender and Binet clinical stage, CD38 and ZAP-70 expression
normal trisomy 12 del 11q22 del 17q13 del 13q14.3 2 simultaneousabnormalities
Age
< 60 3 0 0 2 0 2
> 60 11 2 0 1 5 3
Gender
M 9 1 0 2 5 0
F 5 1 0 1 0 5
Binet stage
A 9 1 0 1 2 2
B 1 0 0 2 3 2
C 4 1 0 0 0 1
CD 38
Positive 4 0 0 3 0 3
Negative 10 2 0 0 5 2
ZAP-70*
Positive 6 2 0 3 1 1
Negative 7 0 0 0 4 4
Total (n) 14 2 0 3 5 5
    % 48,3 6,9 0 10,3 17,2 17,2
Pbs*.: ZAP-70 was realized in 29 patients
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trisomic clone decreases significantly after successful
chemotherapy. However, the acquisition of an extra
chromosome 12 in CLL has so far been reported only in
patients with signs of transformation to Richter's syndrome.
The patients with trisomy 12 in this study also presented
CD38 and/or ZAP-70+ indicating an unfavorable disease
course which was afterwards confirmed.
Using specific locus probe for the chromosome 11q22
(ATM locus) we found a deletion in only one (3.4%) patient
out of 29, and that alteration was associated to the 13q14
deletion. 11q22 deletion incidence in this study was lower
compared to most of published data.26
Previous studies in CLL reveal that ATM is a protein
located in the chromosome 11q22. ATM protects the integrity
of the genome by arresting cell cycle and activating DNA-
repair pathways.26,27 11q22 deletions have been associated
with aggressive clinical courses of the disease,28,16 a fact also
observed here since this patient died of aggressive disease
within 33 months.
We detected a mono-allelic deletion of 17p in 17.2%
of patients, similar to other studies.29
p53, a transcription factor that is activated by DNA
breaks, inducing cell apoptosis or cell cycle arrest. Thus
p53 is critical for either the repair or death of cells with
DNA damage and acts against the development of abnormal
cell clones.30 In patients with CLL, the mutation of p53 gene
has been detected in about 10-15% by molecular techniques.
The 17p13.1 deletion is considered to be a marker of
advanced disease and resistance to drugs.31
In the present study we found 34.5% of mono-allelic
deletions for chromosome 13q14, an incidence similar to
literature data (15-30%).32 The region of 13q14.3 telomeric
to the retinoblastoma (RB1) gene is
often deleted in CLL and is thought
to have a tumor suppressor function.
Structural abnormalities of
chromosome 13 have been associated
with early clinical stage, typical
morphology and as good prognosis
as cases with normal karyotypes.23,32
To better assess the
chromosomes aberrations regarding
other prognostic factors in CLL, we
separated the patients in two
cytogenetic groups: favorable (13q
deletion in isolation and no
alteration) and unfavorable outcome
(trisomy 12, 17p13 deletion, 11q22
deletion and two simultaneous
alterations).
We found that in relation to
patients' age, the unfavorable
alterations were more frequent
among the young (57% of the <60
years) while these alterations were found in only 27.2% of
elderly patients.
In an analysis of prognostic factors in CLL including
the importance of the age, gender and response to treatment
in survival, Catovsky et al (1989)33 suggested that age is an
adverse prognostic factor. Bosch and Montserrat (2002)34
also affirmed that elderly patients have consistently shown
poor prognosis, however, the reasons for these differences
have not been well analyzed. Older individuals have an
increased incidence of concomitant diseases. The presence
of comorbidities, usually not noticed in a younger population,
has a major impact on survival and on the ability to tolerate
treatments. In fact, unrelated diseases are an important cause
of death in older patients. Notwithstanding, the higher
incidence of unfavorable cytogenetic alterations in the
younger individuals observed in this study is pointing out
to a valuable prognostic factor, related to the biology of the
disease, and useful to predict the clinical evolution of the
patient, specially among this set of population that die more
frequently due to causes directly related to CLL.
In relation to gender, there was prevalence of females
(70%) in the group of unfavorable prognoses. The impact
of gender on prognosis is controversial, with some studies
showing no difference in survival and others demonstrating
a better survival for females. The reasons for this statement
are complex. Most of the explanations for a better survival
rate in women with CLL is the longer life expectancy of
women in the general population, as well as the fact that
the disease tends to present fewer unfavorable features in
women,34 an observation not confirmed in the present study.
In relation to the Binet's staging system, among the
patients with worse cytogenetic prognoses, there was a
Table 3
Comparison of unfavorable v. favorable cytogenetics alterations detected by FISH in patients with CLL in relation
to age, gender, Binet clinical stage, CD 38 and ZAP-70 expression
Unfavorable Favorable
Trisomy 12, del 17p13, del 11q22 e
2 simultaneous alterations
No cytogenetic alteration and del
13q14
(N) (N=10) n (%) (N=19) n (%) p*
Age
> 60 22 6 (27,3%) 16 (72,7%)
< 60 7 4 (57%) 3 ( 43%) F = 0,19
Gender
M 17 3 (30%) 14 (74%)
F 12 7 (70%) 5 (26%) F = 0,04
Binet
A 15 4 (40%) 11(58%)
B + C 14 6 (60% 8 (42%) F = 0,44
CD38 + 10 6 (60%) 4 (21%)
CD28 - 4 (40%) 15 (78%) F = 0,051
ZAP 70 + 13 6 (60%) 7 (39%)
ZAP 70 - 15 4 (40%) 11 (61%) F = 0,43
p*: F = FISHER´s test
ZAP-70: 29 patients studied
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prevalence of B and C, while in the favorable group stage A
patients prevailed, as expected. Lazaridou et al (2000)25
demonstrated the relation between the number of
abnormalities and the disease stage. Patients in stage A of
Binet, had an average of less than one abnormality, those in
stage B, 1.5 and those in stage C presented 2.6 abnormalities,
demonstrating the relation between complex alterations and
worst prognosis.
CD38 is a transmembrane glycoprotein, present in
most of T, B, natural killer, plasma cells, monocytes,
macrophages and erythrocytes. Studies of the CD38
expression in CLL cells demonstrated that patients
expressing this antigen in the cellular surface presented
worse prognoses.8,35 We found that patients with poor
prognosis cytogenetics were more frequently CD38+, as well.
Abbasi et al (2003)36 noticed that CD38 negative patients
seemed to have larger probability of presenting isolated 13q
deletion while Dewald et al (2003)37 demonstrated that
CD38+ patients were more likely to have multiple FISH
anomalies, and indicated that favorable (13q -) and un-
favorable (+12,11q-,17p -) FISH anomalies can occur in
stable and progressive diseases. FISH results together with
CD38 expression may provide valuable prognostic
information in CLL patients.
The expression of ZAP-70 (zeta-associated protein 70),
a protein tyrosine kinase involved with the cellular signaling
of T cells, can be evaluated through flow cytometric analysis,
immunohistochemistry or immunoblot techniques, allowing
the identification of worse survival when positive.38 In the
group of unfavorable cytogenetics, 60% were also ZAP-70
positive. Grever et al (2003)39 demonstrated in selected high
risk groups (17p-, 11q-) where progression is heterogeneous,
that ZAP-70 may also distinguish patients who have a
predisposition to early versus late disease progression. ZAP-
70 determinations in patients with CLL complement
cytogenetic data and may assist in planning therapeutic
decisions.
Additionally, in respect to VH mutation status, six of
CLL patients were mutated and nine unmutated in the
present study. Stilgenbauer et al (2002),40 analyzed genetic
parameters in relation to prognosis and found that the overall
incidence of genomic aberrations was similar in the VH
mutated and unmutated groups. Favorable aberrations were
more frequently observed in the VH mutated group, whereas
unfavorable aberrations were overrepresented in the
unmutated group.
Conclusion
We conclude that cytogenetics and FISH are important
prognostic indicators and should be correlated with other
prognostic parameters such as ZAP-70, CD38 and VH
mutation status, at diagnosis, in order to predict clinical
course.
Resumo
A leucemia linfocítica crônica (LLC) é o tipo de leucemia mais
prevalente no Ocidente e é caracterizada por curso clínico extre-
mamente variável. O objetivo deste estudo foi detectar as anoma-
lias cromossômicas mais freqüentes em pacientes com LLC, em-
pregando a técnica FISH, e correlacioná-las com idade, sexo,
estádio clínico, expressão de CD 38 e ZAP-70.  Foram encontra-
das alterações cromossômicas em 51,7% dos pacientes. A mais
freqüente foi a del 13q14, observada em 34,5% dos casos e que
esteve associada a outras anomalias em 17,2%. Deleção 17p13
foi encontrada em 17,2% e trissomia 12 em 13,8% (isolada em
6,9% e associada à del 13q14 em 6,9%). Deleção 11q22 foi ob-
servada em um caso em concomitância à del 13q14. Para melhor
avaliar a relação entre alteração cromossômica e outros fatores
prognósticos em LLC, dois grupos citogenéticos foram conside-
rados: favorável (deleção 13q isolada e ausência de alterações) e
desfavorável (trissomia 12, deleção 17p13, deleção 11q22 e duas
anomalias simultâneas). As alterações desfavoráveis foram mais
freqüentemente observadas em indivíduos jovens (<60 anos) e em
mulheres (70%)(p=0,04). Em relação ao sistema de estadiamento
de Binet, houve tendência dos pacientes com alterações cro-
mossômicas desfavoráveis apresenteram-se nos estágios B e C
enquanto no grupo favorável prevaleceram aqueles com estágio
A. Em adição, pacientes com achados citogenéticos de prognósti-
co desfavorável tiveram tendência a expressar proteínas CD 38 e
ZAP-70.Rev. bras. hematol. hemoter. 2006;28(1):5-10.
Palavras-chave: Leucemia linfocítica crônica; (FISH); cito-
genética.
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